Value Sense
SLN
Silence Therapeutics plc (SLN)
Last Price$4.3(4.0%)
Market Cap$211.4B
LTM Cash & Cash Equivalents
$82.9M
YoY Growth
+15.5%
3Y CAGR
-4.9%
5Y CAGR
+37.9%
Stock quality & Intrinsic value
6/10
99.8% overvalued
SLN
is (99.8%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Silence Therapeutics plc Cash & Cash Equivalents

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Cash & Cash Equivalents
$5,042.6K
$15.6M
$17.3M
$20.2M
$4,871.6K
$1,828.1K
$5,562.9K
$5,733.1K
$14.5M
$26.3M
$26.3M
$76.5M
$48.1M
$57.7M
$27.4M
$17.9M
$37.5M
$99.5M
$66.2M
$68.7M
SLN
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for SLN and see if it's the right time to invest.
Dive in

Silence Therapeutics plc (SLN) Cash & Cash Equivalents comparison analysis

General

LTM Cash & Cash Equivalents

Growth

Company name

YoY growth

3Y CAGR

5Y CAGR

Silence Therapeutics plc logo
Silence Therapeutics plcSLN
$82.9M
15.5%
(4.7%)
35.6%
Median Peer Set
$1,692.5M
(6.0%)
9.5%
10.0%
BioNTech SE logo
BioNTech SEBNTX
$10.7B
(24.9%)
59.0%
83.4%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
$4,569.6M
(55.9%)
(12.4%)
8.0%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
$2,701.9M
(11.9%)
25.0%
25.8%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
$2,166.7M
1.7%
13.5%
0.2%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
$1,697.2M
40.5%
23.8%
18.1%
Incyte Corporation logo
Incyte CorporationINCY
$1,687.8M
(47.5%)
(6.4%)
(1.6%)
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
$966.4M
18.9%
5.6%
12.0%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
$104.9M
46.8%
13.5%
22.8%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
$0.0
(100.0%)
(100.0%)
(100.0%)
argenx SE logo
argenx SEARGX
N/A
N/A
N/A
N/A

SLN key stats

USD
GBP
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.3
0.0%
0.9
217.9%
3.6
287.2%
8.1
125.8%
4.1
(49.5%)
2.7
(34.1%)
3.7
35.5%
1.1
(69.6%)
0.3
(76.8%)
0.2
(29.1%)
0.0
(86.5%)
0.0
(100.0%)
1.0
0.0%
0.0
(98.0%)
0.0
(100.0%)
0.3
0.0%
7.0
2,158.4%
17.1
142.7%
21.7
26.8%
31.6
45.7%
Cost of Goods Sold (COGS)0.00.00.09.712.47.99.05.45.48.814.610.911.810.213.00.04.810.313.512.8
Gross Profit
% margin
0.3
100.0%
0.9
100.0%
3.6
100.0%
(1.6)
(19.7%)
(8.3)
(203.8%)
(5.2)
(194.4%)
(5.3)
(146.0%)
(4.3)
(384.3%)
(5.1)
(1,972.4%)
(8.7)
(4,727.4%)
(14.6)
(59,126.7%)
(10.9)
0.0%
(10.8)
(1,031.3%)
(10.2)
(49,543.8%)
(13.0)
0.0%
0.3
100.0%
2.2
31.3%
6.8
39.9%
8.2
37.8%
18.7
59.3%
Operating Expenses6.58.011.49.76.16.67.94.29.514.420.014.917.218.627.529.348.269.868.380.4
Research & Development Expenses (R&D)3.13.05.99.712.47.99.05.45.48.814.610.911.810.213.017.025.942.344.054.7
Selling, General & Administrative Expenses (SG&A)3.45.05.610.06.15.07.94.24.15.55.44.15.48.314.512.318.027.524.325.7
Operating Income
% margin
(6.2)
(2,118.2%)
(7.1)
(765.8%)
(7.9)
(219.2%)
(11.6)
(143.0%)
(14.4)
(352.7%)
(11.8)
(438.4%)
(13.4)
(365.9%)
(9.3)
(833.7%)
(41.7)
(16,143.6%)
(14.2)
(7,753.8%)
(20.0)
(80,846.7%)
(14.9)
0.0%
(16.1)
(1,546.2%)
(18.5)
(89,943.8%)
(27.5)
0.0%
(29.0)
(9,317.2%)
(46.0)
(654.3%)
(63.0)
(369.0%)
(60.1)
(277.7%)
(61.7)
(195.5%)
Interest Income0.20.50.61.10.70.10.10.10.00.10.20.32.10.30.10.00.20.00.31.8
Interest Expense0.10.00.00.0(0.1)0.00.10.00.00.00.00.00.00.00.00.20.40.00.10.0
Pre-tax Income(6.1)(6.6)(7.3)(10.5)(13.8)(11.8)(13.6)(9.2)(41.7)(14.1)(19.7)(14.4)(14.1)(4.9)(27.4)(29.2)(46.3)(63.1)(58.6)(62.6)
Income Tax
% effective tax rate
(0.6)
10.6%
(0.1)
1.4%
(0.2)
2.9%
(0.3)
2.6%
(0.7)
4.8%
(0.1)
0.5%
0.2
(1.6%)
(0.1)
0.9%
(0.0)
0.1%
(0.1)
0.8%
(1.5)
7.4%
(4.3)
29.5%
(2.6)
18.5%
(2.8)
57.1%
(2.8)
10.3%
(4.2)
14.4%
(4.5)
9.7%
(8.9)
14.1%
(8.5)
14.5%
(8.8)
14.0%
Net Income
% margin
(5.4)
(1,859.1%)
(6.5)
(704.3%)
(7.0)
(196.5%)
(10.2)
(126.2%)
(13.8)
(336.6%)
(11.7)
(433.6%)
(13.6)
(371.7%)
(9.2)
(826.7%)
(41.7)
(16,125.2%)
(14.1)
(7,694.0%)
(18.3)
(73,920.0%)
(10.2)
0.0%
(11.4)
(1,096.1%)
(2.1)
(10,112.5%)
(24.6)
0.0%
(25.0)
(8,025.4%)
(41.8)
(594.0%)
(54.2)
(317.4%)
(50.1)
(231.4%)
(53.8)
(170.5%)
EPS(34.04)(16.07)(11.11)(13.19)(17.23)(13.03)(7.33)(2.95)(6.51)(0.95)(1.09)(0.47)(0.49)(0.09)(1.05)(1.00)(1.53)(1.83)(1.56)(1.45)
Diluted EPS(34.04)(16.07)(11.11)(13.19)(17.23)(13.03)(7.33)(2.95)(6.51)(0.95)(1.09)(0.47)(0.49)(0.09)(1.05)(1.00)(1.53)(1.83)(1.56)(1.45)
EBITDA
% margin
(5.9)
(2,011.3%)
(6.2)
(671.5%)
(6.6)
(184.2%)
(10.6)
(131.4%)
(13.8)
(336.8%)
(11.1)
(413.1%)
(12.6)
(345.3%)
(8.7)
(780.8%)
(8.4)
(3,255.8%)
(13.7)
(7,500.0%)
(19.4)
(78,633.3%)
(14.7)
0.0%
(15.7)
(1,506.0%)
(4.3)
(20,793.8%)
(26.9)
0.0%
(28.5)
(9,161.9%)
(45.6)
(648.5%)
(62.5)
(365.9%)
(59.2)
(273.6%)
(61.9)
(196.2%)

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Silence Therapeutics plc's Cash & Cash Equivalents?

As of today, Silence Therapeutics plc's last 12-month Cash & Cash Equivalents is $82.9M, based on the financial report for Sep 30, 2024 (Q3’2024).

2) What is Silence Therapeutics plc's Cash & Cash Equivalents growth rate?

Over the last year, Silence Therapeutics plc's Cash & Cash Equivalents growth was 15.5%. The average annual Cash & Cash Equivalents growth rates for Silence Therapeutics plc have been N/A over the past three years, 37.9% over the past five years.

3) Is Silence Therapeutics plc's Cash & Cash Equivalents growth rate Good?

Over the last year, Silence Therapeutics plc's Cash & Cash Equivalents growth was 15.5%, which is higher than industry growth of (0.2%). It indicates that Silence Therapeutics plc's Cash & Cash Equivalents growth is Good.

4) How does Silence Therapeutics plc's Cash & Cash Equivalents growth rate compare to its peers?

Over the last year, Silence Therapeutics plc's Cash & Cash Equivalents growth was 15.5%, which is higher than peer median growth of (30.4%). The list of peers includes BNTX, VRTX, BGNE, NVO, UTHR, INCY, ALNY, SMMT, REGN, ARGX etc.